At what age is the herpes zoster vaccine recommended for administration?

Herpes Zoster Vaccine Age Recommendation

The herpes zoster vaccine (recombinant zoster vaccine, RZV/Shingrix) is recommended starting at age 50 years for immunocompetent adults, and at age 19 years for immunocompromised adults. 1, 2

Standard Recommendation for Immunocompetent Adults

For healthy adults, vaccination should begin at age 50 years or older with a 2-dose series of RZV (Shingrix) given 2-6 months apart (minimum interval 4 weeks). 1 This represents the current standard across major guidelines, with RZV being the strongly preferred vaccine over the older live zoster vaccine (ZVL/Zostavax). 2

Key Points for Immunocompetent Adults:

• Age 50-59 years: RZV demonstrates 97.2% vaccine efficacy in preventing herpes zoster 2
• Age ≥60 years: RZV shows 89.8-91.3% efficacy, significantly outperforming ZVL which only achieves 64% efficacy in this age group 2
• Age ≥70 years: RZV maintains 91.3% efficacy against herpes zoster and 88.8% against postherpetic neuralgia 2

The superiority of RZV is clear: protection persists above 83% for up to 8 years and remains at 73% at 10 years, whereas ZVL efficacy wanes dramatically to only 21.2% by 7-11 years post-vaccination. 2

Immunocompromised Adults

For immunocompromised individuals, RZV is recommended starting at age 19 years. 3 This expanded indication was approved in 2021 and represents a critical advancement, as immunocompromised adults face substantially higher risk of herpes zoster at younger ages—comparable to or exceeding the risk in immunocompetent adults aged 50+ years. 4

Immunocompromising Conditions Include:

• Solid cancers (RZV is the preferred vaccine) 2
• HIV infection
• Hematologic malignancies
• Immunosuppressive therapy
• Solid organ transplantation

Important contraindication: The live zoster vaccine (ZVL) is absolutely contraindicated in immunocompromised patients, including those with HIV and CD4 count <200 cells/μL. 1 Only RZV should be used in these populations.

Dosing Schedule

The standard regimen is 2 doses of RZV administered intramuscularly, 2-6 months apart (minimum 4-week interval). 1, 5 If a dose is given too soon (before 4 weeks), it should be repeated. 1

Prior Vaccination Considerations:

• If previously received ZVL (Zostavax), administer RZV at least 2 months after ZVL 1
• Previous history of herpes zoster does NOT preclude vaccination—RZV is still recommended 1

Common Pitfalls to Avoid

1. Don't wait until age 60: While older guidelines recommended vaccination at 60, current evidence supports starting at age 50 for all immunocompetent adults 1, 2

2. Don't use ZVL in immunocompromised patients: This is an absolute contraindication that could cause serious harm 1

3. Don't skip the second dose: The 2-dose series is essential for optimal protection; single-dose efficacy is inadequate

4. Pregnancy timing: Consider delaying RZV until after pregnancy if otherwise indicated, though it's not absolutely contraindicated like ZVL 1

Safety Profile

RZV causes more injection-site reactions (pain, redness, swelling in 9.5%) and systemic symptoms (myalgia, fatigue, headache in 11.4%) compared to placebo, but shows no difference in serious adverse events or deaths. 2, 6 These reactogenic effects, while common, should not deter vaccination given the substantial disease burden prevented.